Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

Figure 4

Tumor-infiltrating immune cells and tumor microenvironment (TME) in high- and low-risk CRC patients. (a) Distribution of 22 tumor-infiltrating immune cells in 516 CRC patients. (b) Comparison of the proportions of tumor-infiltrating immune cells between the high- and low-risk groups. (c–f) Associations of the TFS risk score with the ESTIMATE score, immune score, stromal score, and tumor purity in CRC patients in the TCGA cohort.

(a)

(b)

(c)

(d)

(e)

(f)